PuSH - Publication Server of Helmholtz Zentrum München

172 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
61.
Marahrens, L.* et al.: Patients' preferences for involvement in the decision-making process for treating diabetic retinopathy. BMC Ophthalmol. 17:139 (2017)
62.
Marahrens, L.* et al.: Umsetzung der Nationalen VersorgungsLeitlinie (NVL) zur Therapie des Diabetes mellitus Typ 2 in diabetologischen Schwerpunktpraxen. Dtsch. Med. Wochenschr. 142, e131-e139 (2017)
63.
Ordelheide, A.-M. et al.: Common variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations. PLoS ONE 12:e177148 (2017)
64.
Peter, A. et al.: The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. Am. J. Physiol. Endocrinol. Metab. 314, E266-E273 (2017)
65.
Schmid, V.* et al.: Non-alcoholic fatty liver disease and impaired proinsulin conversion as newly identified predictors of the long-term non-response to a lifestyle intervention for diabetes prevention: Results from the TULIP study. Diabetologia 60, 2341-2351 (2017)
66.
Siegel-Axel, D. et al.: The 'fatty kidney': Crosstalk of renal sinus fat with glomerular cells under the influence of the hepatokine fetuin-A. Diabetologia 60, S483-S483 (2017)
67.
Stirm, L. ; Fritsche, L. ; Fritsche, A. ; Häring, H.-U. & Staiger, H.: Apelinergic system in placenta of women with gestational diabetes. Diabetologia 60, S44-S44 (2017)
68.
Wagner, R. et al.: Nonsuppressed glucagon after glucose challenge as a potential predictor for glucose tolerance. Diabetes 66, 1373-1379 (2017)
69.
Wagner, R. et al.: The protective effect of human renal sinus fat on glomerular cells is reversed by the hepatokine fetuin-A. Sci. Rep. 7:2261 (2017)
70.
Wagner, R. et al.: Erratum to: A novel insulin sensitivity index particularly suitable to measure insulin sensitivity during gestation. Acta Diabetol. 54, 713-714 (2017)
71.
Wagner, R. et al.: Excessive fuel availability amplifies the FTO-mediated obesity risk: Results from the TUEF and Whitehall II studies. Sci. Rep. 7:15486 (2017)
72.
Wood, A.R.* et al.: A genome-wide association study of IVGTT-based measures of first-phase insulin secretion refines the underlying physiology of type 2 diabetes variants. Diabetes 66, 2296-2309 (2017)
73.
Artunc, F. et al.: The impact of insulin resistance on the kidney and vasculature. Nat. Rev. Nephrol. 12, 721-737 (2016)
74.
Böhm, A. et al.: TGFβ contributes to impaired exercise response by suppression of mitochondrial key regulators in skeletal muscle. Diabetes 65, 2849-2861 (2016)
75.
Bonadonna, R.C.* et al.: Switching to insulin glargine 300 U/ML (GLA-300): Benefits vs GLA-100 by duration of prior basal insulin therapy. Diabetes Technol. Ther. 18, A31 (2016)
76.
Frank, S.* et al.: Dopamine depletion reduces food-related reward activity independent of BMI. Neuropsychopharmacology 41, 1551-1559 (2016)
77.
Frank, S.* et al.: Neuronal food reward activity in patients with type 2 diabetes with improved glycemic control after bariatric surgery. Diabetes Care 39, 1311-1317 (2016)
78.
Heni, M. et al.: Interaction between the obesity-risk gene FTO and the dopamine D2 receptor gene ANKK1/TaqIA on insulin sensitivity. Diabetologia 59, 1-10 (2016)
79.
Kullmann, S. et al.: Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol. Rev. 96, 1169-1209 (2016)
80.
Lutz, S.Z. et al.: Genetic variation in the 11β-hydroxysteroid-dehydrogenase 1 gene determines NAFLD and visceral obesity. J. Clin. Endocrinol. Metab. 101, 4743-4751 (2016)